Related Experiment Video

Updated: Apr 18, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Management of advanced bladder cancer in the era of targeted therapies

A Soave1, O Engel, G Von Amsberg

  • 1Department of Urology, University Medical Center Hamburg‑Eppendorf, Hamburg, Germany - mrink@uke.de.

Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology
|January 22, 2015
PubMed

Insights

Targeted therapies offer a promising alternative to standard chemotherapy for advanced urothelial carcinoma of the bladder (UCB). These precision treatments focus on specific genomic mutations, potentially improving efficacy and reducing side effects in UCB patients.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Systemic chemotherapy is the standard treatment for advanced and metastatic urothelial carcinoma of the bladder (UCB).
  • Chemotherapy exhibits limited efficacy and frequent side effects in a significant proportion of UCB patients.
  • Genomic heterogeneity in UCB presents challenges but also reveals cancer-specific therapeutic targets.

Purpose of the Study:

  • To review current findings on targeted therapies for advanced and metastatic urothelial carcinoma of the bladder.
  • To elucidate the potential benefits and limitations of targeted therapy in UCB treatment.
  • To discuss future perspectives for precision medicine in UCB.

Main Methods:

  • Comprehensive literature review of recent studies on targeted therapies in advanced and metastatic UCB.
  • Analysis of molecular-genetic investigations identifying therapeutic targets in UCB.
  • Synthesis of data on the clinical impact, efficacy, and side effect profiles of targeted agents.

Main Results:

  • Targeted therapies aim to inhibit cancer cell growth by focusing on specific genomic variations.
  • These therapies hold potential for improved efficacy and reduced toxicity compared to conventional chemotherapy.
  • The clinical impact of targeted therapies in UCB is still under investigation, with ongoing research.

Conclusions:

  • Targeted therapies represent a shift towards individualized treatment strategies for UCB based on molecular profiles.
  • Further research is needed to fully establish the role and optimize the use of targeted therapies in UCB.
  • Precision medicine approaches may overcome chemo-resistance and improve outcomes for patients with advanced and metastatic UCB.

More Related Videos

Culture of Bladder Cancer Organoids as Precision Medicine Tools08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

5.7K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K